Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy

Ki Young Choi, Hong Yeol Yoon, Jong Ho Kim, Sang Mun Bae, Rang Woon Park, Young Mo Kang, In-San Kim, Ick Chan Kwon, Kuiwon Choi, Seo Young Jeong, Kwang Meyung Kim, Jae Hyung Park

Research output: Contribution to journalArticle

265 Citations (Scopus)

Abstract

Tumor targetability and site-specific drug release of therapeutic nanoparticles are key factors for effective cancer therapy. In this study, poly(ethylene glycol) (PEG)-conjugated hyaluronic acid nanoparticles (P-HA-NPs) were investigated as carriers for anticancer drugs including doxorubicin and camptothecin (CPT). P-HA-NPs were internalized into cancer cells (SCC7 and MDA-MB-231) via receptor-mediated endocytosis, but were rarely taken up by normal fibroblasts (NIH-3T3). During in vitro drug release tests, P-HA-NPs rapidly released drugs when incubated with cancer cells, extracts of tumor tissues, or the enzyme Hyal-1, which is abundant in the intracellular compartments of cancer cells. CPT-loaded P-HA-NPs (CPT-P-HA-NPs) showed dose-dependent cytotoxicity to cancer cells (MDA-MB-231, SCC7, and HCT 116) and significantly lower cytotoxicity against normal fibroblasts (NIH-3T3) than free CPT. Unexpectedly, high concentrations of CPT-P-HA-NPs demonstrated greater cytotoxicity to cancer cells than free CPT. An in vivo biodistribution study indicated that P-HA-NPs selectively accumulated into tumor sites after systemic administration into tumor-bearing mice, primarily due to prolonged circulation in the blood and binding to a receptor (CD44) that was overexpressed on the cancer cells. In addition, when CPT-P-HA-NPs were systemically administrated into tumor-bearing mice, we saw no significant increases in tumor size for at least 35 days, implying high antitumor activity. Overall, P-HA-NPs showed promising potential as a drug carrier for cancer therapy.

Original languageEnglish
Pages (from-to)8591-8599
Number of pages9
JournalACS Nano
Volume5
Issue number11
DOIs
Publication statusPublished - 2011 Nov 22
Externally publishedYes

Fingerprint

Hyaluronic acid
Hyaluronic Acid
Polyethylene glycols
therapy
cancer
Nanoparticles
nanoparticles
acids
Tumors
tumors
Cells
drugs
Camptothecin
Bearings (structural)
Cytotoxicity
multiple docking adapters
fibroblasts
Fibroblasts
Pharmaceutical Preparations
mice

Keywords

  • camptothecin
  • drug release
  • Hyal-1
  • hyaluronic acid
  • nanoparticle
  • tumor targeting

ASJC Scopus subject areas

  • Engineering(all)
  • Materials Science(all)
  • Physics and Astronomy(all)

Cite this

Choi, K. Y., Yoon, H. Y., Kim, J. H., Bae, S. M., Park, R. W., Kang, Y. M., ... Park, J. H. (2011). Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy. ACS Nano, 5(11), 8591-8599. https://doi.org/10.1021/nn202070n

Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy. / Choi, Ki Young; Yoon, Hong Yeol; Kim, Jong Ho; Bae, Sang Mun; Park, Rang Woon; Kang, Young Mo; Kim, In-San; Kwon, Ick Chan; Choi, Kuiwon; Jeong, Seo Young; Kim, Kwang Meyung; Park, Jae Hyung.

In: ACS Nano, Vol. 5, No. 11, 22.11.2011, p. 8591-8599.

Research output: Contribution to journalArticle

Choi, KY, Yoon, HY, Kim, JH, Bae, SM, Park, RW, Kang, YM, Kim, I-S, Kwon, IC, Choi, K, Jeong, SY, Kim, KM & Park, JH 2011, 'Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy', ACS Nano, vol. 5, no. 11, pp. 8591-8599. https://doi.org/10.1021/nn202070n
Choi KY, Yoon HY, Kim JH, Bae SM, Park RW, Kang YM et al. Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy. ACS Nano. 2011 Nov 22;5(11):8591-8599. https://doi.org/10.1021/nn202070n
Choi, Ki Young ; Yoon, Hong Yeol ; Kim, Jong Ho ; Bae, Sang Mun ; Park, Rang Woon ; Kang, Young Mo ; Kim, In-San ; Kwon, Ick Chan ; Choi, Kuiwon ; Jeong, Seo Young ; Kim, Kwang Meyung ; Park, Jae Hyung. / Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy. In: ACS Nano. 2011 ; Vol. 5, No. 11. pp. 8591-8599.
@article{807e305385694ca5bebe5db27cef2c0d,
title = "Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy",
abstract = "Tumor targetability and site-specific drug release of therapeutic nanoparticles are key factors for effective cancer therapy. In this study, poly(ethylene glycol) (PEG)-conjugated hyaluronic acid nanoparticles (P-HA-NPs) were investigated as carriers for anticancer drugs including doxorubicin and camptothecin (CPT). P-HA-NPs were internalized into cancer cells (SCC7 and MDA-MB-231) via receptor-mediated endocytosis, but were rarely taken up by normal fibroblasts (NIH-3T3). During in vitro drug release tests, P-HA-NPs rapidly released drugs when incubated with cancer cells, extracts of tumor tissues, or the enzyme Hyal-1, which is abundant in the intracellular compartments of cancer cells. CPT-loaded P-HA-NPs (CPT-P-HA-NPs) showed dose-dependent cytotoxicity to cancer cells (MDA-MB-231, SCC7, and HCT 116) and significantly lower cytotoxicity against normal fibroblasts (NIH-3T3) than free CPT. Unexpectedly, high concentrations of CPT-P-HA-NPs demonstrated greater cytotoxicity to cancer cells than free CPT. An in vivo biodistribution study indicated that P-HA-NPs selectively accumulated into tumor sites after systemic administration into tumor-bearing mice, primarily due to prolonged circulation in the blood and binding to a receptor (CD44) that was overexpressed on the cancer cells. In addition, when CPT-P-HA-NPs were systemically administrated into tumor-bearing mice, we saw no significant increases in tumor size for at least 35 days, implying high antitumor activity. Overall, P-HA-NPs showed promising potential as a drug carrier for cancer therapy.",
keywords = "camptothecin, drug release, Hyal-1, hyaluronic acid, nanoparticle, tumor targeting",
author = "Choi, {Ki Young} and Yoon, {Hong Yeol} and Kim, {Jong Ho} and Bae, {Sang Mun} and Park, {Rang Woon} and Kang, {Young Mo} and In-San Kim and Kwon, {Ick Chan} and Kuiwon Choi and Jeong, {Seo Young} and Kim, {Kwang Meyung} and Park, {Jae Hyung}",
year = "2011",
month = "11",
day = "22",
doi = "10.1021/nn202070n",
language = "English",
volume = "5",
pages = "8591--8599",
journal = "ACS Nano",
issn = "1936-0851",
publisher = "American Chemical Society",
number = "11",

}

TY - JOUR

T1 - Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy

AU - Choi, Ki Young

AU - Yoon, Hong Yeol

AU - Kim, Jong Ho

AU - Bae, Sang Mun

AU - Park, Rang Woon

AU - Kang, Young Mo

AU - Kim, In-San

AU - Kwon, Ick Chan

AU - Choi, Kuiwon

AU - Jeong, Seo Young

AU - Kim, Kwang Meyung

AU - Park, Jae Hyung

PY - 2011/11/22

Y1 - 2011/11/22

N2 - Tumor targetability and site-specific drug release of therapeutic nanoparticles are key factors for effective cancer therapy. In this study, poly(ethylene glycol) (PEG)-conjugated hyaluronic acid nanoparticles (P-HA-NPs) were investigated as carriers for anticancer drugs including doxorubicin and camptothecin (CPT). P-HA-NPs were internalized into cancer cells (SCC7 and MDA-MB-231) via receptor-mediated endocytosis, but were rarely taken up by normal fibroblasts (NIH-3T3). During in vitro drug release tests, P-HA-NPs rapidly released drugs when incubated with cancer cells, extracts of tumor tissues, or the enzyme Hyal-1, which is abundant in the intracellular compartments of cancer cells. CPT-loaded P-HA-NPs (CPT-P-HA-NPs) showed dose-dependent cytotoxicity to cancer cells (MDA-MB-231, SCC7, and HCT 116) and significantly lower cytotoxicity against normal fibroblasts (NIH-3T3) than free CPT. Unexpectedly, high concentrations of CPT-P-HA-NPs demonstrated greater cytotoxicity to cancer cells than free CPT. An in vivo biodistribution study indicated that P-HA-NPs selectively accumulated into tumor sites after systemic administration into tumor-bearing mice, primarily due to prolonged circulation in the blood and binding to a receptor (CD44) that was overexpressed on the cancer cells. In addition, when CPT-P-HA-NPs were systemically administrated into tumor-bearing mice, we saw no significant increases in tumor size for at least 35 days, implying high antitumor activity. Overall, P-HA-NPs showed promising potential as a drug carrier for cancer therapy.

AB - Tumor targetability and site-specific drug release of therapeutic nanoparticles are key factors for effective cancer therapy. In this study, poly(ethylene glycol) (PEG)-conjugated hyaluronic acid nanoparticles (P-HA-NPs) were investigated as carriers for anticancer drugs including doxorubicin and camptothecin (CPT). P-HA-NPs were internalized into cancer cells (SCC7 and MDA-MB-231) via receptor-mediated endocytosis, but were rarely taken up by normal fibroblasts (NIH-3T3). During in vitro drug release tests, P-HA-NPs rapidly released drugs when incubated with cancer cells, extracts of tumor tissues, or the enzyme Hyal-1, which is abundant in the intracellular compartments of cancer cells. CPT-loaded P-HA-NPs (CPT-P-HA-NPs) showed dose-dependent cytotoxicity to cancer cells (MDA-MB-231, SCC7, and HCT 116) and significantly lower cytotoxicity against normal fibroblasts (NIH-3T3) than free CPT. Unexpectedly, high concentrations of CPT-P-HA-NPs demonstrated greater cytotoxicity to cancer cells than free CPT. An in vivo biodistribution study indicated that P-HA-NPs selectively accumulated into tumor sites after systemic administration into tumor-bearing mice, primarily due to prolonged circulation in the blood and binding to a receptor (CD44) that was overexpressed on the cancer cells. In addition, when CPT-P-HA-NPs were systemically administrated into tumor-bearing mice, we saw no significant increases in tumor size for at least 35 days, implying high antitumor activity. Overall, P-HA-NPs showed promising potential as a drug carrier for cancer therapy.

KW - camptothecin

KW - drug release

KW - Hyal-1

KW - hyaluronic acid

KW - nanoparticle

KW - tumor targeting

UR - http://www.scopus.com/inward/record.url?scp=81855226471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81855226471&partnerID=8YFLogxK

U2 - 10.1021/nn202070n

DO - 10.1021/nn202070n

M3 - Article

VL - 5

SP - 8591

EP - 8599

JO - ACS Nano

JF - ACS Nano

SN - 1936-0851

IS - 11

ER -